Preoperative platelet-lymphocyte ratio is a superior prognostic biomarker to other systemic inflammatory response markers in non-small cell lung cancer

被引:31
作者
Huang, Qing [1 ]
Diao, Peng [2 ]
Li, Chang-Lin [1 ]
Peng, Qian [2 ]
Xie, Tianpeng [3 ]
Tan, Yan [2 ]
Lang, Jin-Yi [2 ]
机构
[1] Chengdu First Peoples Hosp, Dept Oncol, Chengdu, Peoples R China
[2] Univ Elect Sci & Technol China, Sch Med, Sichuan Canc Ctr, Dept Radiotherapy,Sichuan Canc Hosp & Inst, Chengdu, Sichuan, Peoples R China
[3] Univ Elect Sci & Technol China, Sch Med, Sichuan Canc Ctr, Dept Thorac Surg,Sichuan Canc Hosp & Inst, Chengdu, Sichuan, Peoples R China
关键词
C-reactive protein; lymphocyte-monocyte ratio; neutrophil-lymphocyte ratio; non-small cell lung cancer; platelet-lymphocyte ratio; prognostic factor; POOR SURVIVAL; NEUTROPHIL; THROMBOSPONDIN-1; METAANALYSIS; STATISTICS; SURGERY;
D O I
10.1097/MD.0000000000018607
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Systemic inflammatory response markers are associated with poor survival in many types of malignances. This study aimed to evaluate the prognostic value of preoperative neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), and C-reactive protein (CRP) in patients with non-small cell lung cancer (NSCLC). We retrospectively evaluated 254 NSCLC patients who underwent radical surgery between January 2012 and April 2014 in the Sichuan Provincial Cancer Hospital. The cut-off values of NLR, PLR, LMR, and CRP were determined according to the receiver operating characteristic curve, and the correlation of NLR, PLR, LMR, and CRP with prognosis was analyzed based on the cut-off value. The cut-off value for NLR, PLR, LMR, and CRP were 3.18, 122, 4.04, and 8.8, respectively. Univariate analysis showed that age (P = .022), tumor-node-metastasis (TNM) stage (P < .001), T stage (P = .001), and N stage (P < .001) were significantly correlated with disease-free survival (DFS), while age (P = .011), TNM stage (P < .001), T stage (P = .008), N stage (P < .001), and PLR (P = .001) were significantly correlated with overall survival (OS). In multivariate analysis, age (hazard ratio [HR]: 1.564, 95% confidence interval [CI]: 1.087-2.252, P = .016) and TNM stage (HR: 1.704, 95% CI: 1.061-2.735, P = .027) remained independent risk factors affecting DFS, while age (HR: 1.721, 95% CI: 1.153-2.567, P = .008), TNM stage (HR: 2.198, 95% CI: 1.263-3.824, P = .005), and PLR (HR: 1.850, 95% CI: 1.246-2.746, P = .002) were independent risk factors affecting OS. The preoperative PLR is superior to NLR, LMR, and CRP as a biomarker for evaluating the prognosis of patients undergoing curative surgery for NSCLC.
引用
收藏
页数:9
相关论文
共 38 条
[1]   Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients [J].
Azab, Basem ;
Shah, Neeraj ;
Radbel, Jared ;
Tan, Pamela ;
Bhatt, Vijaya ;
Vonfrolio, Steven ;
Habeshy, Ayman ;
Picon, Antonio ;
Bloom, Scott .
MEDICAL ONCOLOGY, 2013, 30 (01)
[2]   Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[3]   Cancer Statistics in China, 2015 [J].
Chen, Wanqing ;
Zheng, Rongshou ;
Baade, Peter D. ;
Zhang, Siwei ;
Zeng, Hongmei ;
Bray, Freddie ;
Jemal, Ahmedin ;
Yu, Xue Qin ;
He, Jie .
CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) :115-132
[4]   Evidence for an alpha-granular pool of the cytoskeletal protein alpha-actinin in human platelets that redistributes with the adhesive glycoprotein thrombospondin-1 during the exocytotic process [J].
Dubernard, V ;
Arbeille, BB ;
Lemesle, MB ;
Legrand, C .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1997, 17 (10) :2293-2305
[5]   Comparison of the Prognostic Value of Tumour- and Patient-Related Factors in Patients Undergoing Potentially Curative Resection of Oesophageal Cancer [J].
Dutta, Sumanta ;
Crumley, Andrew B. C. ;
Fullarton, Grant M. ;
Horgan, Paul G. ;
McMillan, Donald C. .
WORLD JOURNAL OF SURGERY, 2011, 35 (08) :1861-1866
[6]   Perspectives in anaesthesia for cancer surgery [J].
Forget, Patrice ;
De Kock, Marc .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (03) :353-359
[7]   Biomarkers for lung cancer: clinical uses [J].
Greenberg, Alissa K. ;
Lee, M. Sung .
CURRENT OPINION IN PULMONARY MEDICINE, 2007, 13 (04) :249-255
[8]   Immunity, Inflammation, and Cancer [J].
Grivennikov, Sergei I. ;
Greten, Florian R. ;
Karin, Michael .
CELL, 2010, 140 (06) :883-899
[9]   The IASLC lung cancer staging project: Validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours [J].
Groome, Patti A. ;
Bolejack, Vanessa ;
Crowley, John J. ;
Kennedy, Catherine ;
Krasnik, Mark ;
Sobin, Leslie H. ;
Goldstraw, Peter .
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) :694-705
[10]   Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data [J].
Hoang, T ;
Xu, RH ;
Schiller, JH ;
Bonomi, P ;
Johnson, DH .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (01) :175-183